Our Response to COVID-19

A Letter from CEO and Chairman, Giovanni Caforio, M.D.

March 21, 2020

To our global community:

At an unprecedented time in our history, the global spread of COVID-19 is affecting each of us and the communities in which we live in different ways. Bristol Myers Squibb is taking steps to support the health and safety of our workforce, ensure patients have the medicines they need and support our global communities in relief efforts.  

We have set up an emergency response team to monitor the situation and quickly act on guidance from the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), and our leaders are making quick decisions to ensure we help minimize the spread of the virus and support our people, our patients and our communities.

We are protecting the health and safety of our colleagues and partners. 
We are grounded in science and have implemented several precautions to do what is best for our people. Our global workforce that is able to work from home has been required to do so. We have also instituted business travel, workplace and in-person meeting restrictions. In all markets, direction from local government and health authorities takes precedent over our global company guidelines.

We continue to deliver high-quality medicines to patients.
We are diligently monitoring manufacturing and supply facilities across the globe and, at this time, there are no anticipated disruptions to the supply of our medicines for patients due to COVID-19. We are also working with health authorities and investigators to appropriately manage the ongoing operations of clinical trials. Our highest priorities during this time are protecting the safety of our trial participants and personnel at Bristol Myers Squibb and our clinical trial sites, while ensuring our regulatory compliance and the integrity of our science.   

We are taking every precaution to help minimize the spread of COVID-19.
In addition to work-from-home and meeting restrictions for our workforce, our customer-facing personnel in certain markets are suspending in-person interactions with healthcare facilities staff and providers. We are also using digital technology to ensure continued support for healthcare professionals, patient care and access to our medicines.

We are contributing to COVID-19 relief efforts.    
We are committed to supporting communities deeply affected by the virus. The Bristol Myers Squibb Foundation, an independent charitable organization, is committed to working with global relief partners and, to date has provided more than $5 million in financial support and needed products to response and relief capabilities around the world with more support being provided every day.  

COVID-19 is taking a significant human toll, and our hearts go out to those who have been impacted and everyone managing through this difficult and uncertain time. As a responsible global citizen, we will take all necessary actions to promote public health and carry out our mission of providing life-saving medicines to the patients who depend on us.


This letter originally posted on March 16 and was updated on March 21


More on Our Response